{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:59:26Z","timestamp":1773788366191,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00296-021-04917-0","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:02:50Z","timestamp":1623956570000},"page":"1441-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-7734","authenticated-orcid":false,"given":"Somy","family":"Cherian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-6156","authenticated-orcid":false,"given":"Aby","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-311X","authenticated-orcid":false,"given":"Sakir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-4733","authenticated-orcid":false,"given":"Bazil","family":"Alias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-136X","authenticated-orcid":false,"given":"Manesh","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4392-6140","authenticated-orcid":false,"given":"Ansu K.","family":"Santhosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-2060","authenticated-orcid":false,"given":"Delcey Rachel","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-6290","authenticated-orcid":false,"given":"Narayanan","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-1361","authenticated-orcid":false,"given":"Padmanabha","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"4917_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10067-020-05529-y","volume":"40","author":"S Tariq","year":"2021","unstructured":"Tariq S, Van Eeden C, Tervaert JWC, Osman MS (2021) COVID-19, rheumatic diseases and immune dysregulation-a perspective. Clin Rheumatol 40:433\u2013442. https:\/\/doi.org\/10.1007\/s10067-020-05529-y","journal-title":"Clin Rheumatol"},{"key":"4917_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584:430\u2013436. https:\/\/doi.org\/10.1038\/s41586-020-2521-4","journal-title":"Nature"},{"key":"4917_CR3","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s10067-020-05301-2","volume":"39","author":"CS Santos","year":"2020","unstructured":"Santos CS, Morales CM, \u00c1lvarez ED et al (2020) Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 39:2789\u20132796. https:\/\/doi.org\/10.1007\/s10067-020-05301-2","journal-title":"Clin Rheumatol"},{"key":"4917_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00296-021-04803-9","volume":"41","author":"Q Wang","year":"2021","unstructured":"Wang Q, Liu J, Shao R et al (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41:851\u2013861. https:\/\/doi.org\/10.1007\/s00296-021-04803-9","journal-title":"Rheumatol Int"},{"key":"4917_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-020-04764-5","volume":"41","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41:243\u2013256. https:\/\/doi.org\/10.1007\/s00296-020-04764-5","journal-title":"Rheumatol Int"},{"key":"4917_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/art.41734","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Johnson SR, Anthony DD et al (2017) American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases\u2014version 1. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41734 (ahead of print)","journal-title":"Arthritis Rheumatol"},{"key":"4917_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"4917_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00070-0","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00070-0 (ahead of print)","journal-title":"Lancet Infect Dis"},{"key":"4917_CR9","unstructured":"Information regarding COVID-19 vaccine. https:\/\/www.mohfw.gov.in\/covid_vaccination\/vaccination\/index.html. Accessed 13 May 2021"},{"key":"4917_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220231","author":"CM Connolly","year":"2021","unstructured":"Connolly CM, Ruddy JA, Boyarsky BJ et al (2021) Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220231","journal-title":"Ann Rheum Dis"},{"key":"4917_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220272","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220272","journal-title":"Ann Rheum Dis"},{"key":"4917_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0140-6736(21)00762-5","volume":"397","author":"SD \u00d8stergaard","year":"2021","unstructured":"\u00d8stergaard SD, Schmidt M, Horv\u00e1th-Puh\u00f3 E et al (2021) Thromboembolism and the Oxford\u2013AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 397:1441\u20131443. https:\/\/doi.org\/10.1016\/S0140-6736(21)00762-5","journal-title":"Lancet"},{"key":"4917_CR13","unstructured":"ICMR ethical guidelines. https:\/\/ethics.ncdirindia.org\/ICMR_Ethical_Guidelines.aspx. Accessed 13 May 2021"},{"key":"4917_CR14","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s10067-020-05200-6","volume":"39","author":"P Shenoy","year":"2020","unstructured":"Shenoy P, Ahmed S, Paul A et al (2020) Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India. Clin Rheumatol 39:2757\u20132762. https:\/\/doi.org\/10.1007\/s10067-020-05200-6","journal-title":"Clin Rheumatol"},{"key":"4917_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.07.21255078","author":"AK Singh","year":"2021","unstructured":"Singh AK, Phatak SR, Singh NK et al (2021) Antibody response after first-dose of ChAdOx1-nCOV (CovishieldTM\u00ae) and BBV-152 (CovaxinTM\u00ae) amongst health care workers in India: preliminary results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. medRxiv. https:\/\/doi.org\/10.1101\/2021.04.07.21255078","journal-title":"medRxiv"},{"key":"4917_CR16","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e107","volume":"36","author":"SH Kim","year":"2021","unstructured":"Kim SH, Wi YM, Yun SY et al (2021) Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci 36:e107. https:\/\/doi.org\/10.3346\/jkms.2021.36.e107","journal-title":"J Korean Med Sci"},{"key":"4917_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79:39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","journal-title":"Ann Rheum Dis"},{"key":"4917_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.berh.2019.03.006","volume":"32","author":"PKK Wong","year":"2018","unstructured":"Wong PKK, Hanrahan P (2018) Management of vaccination in rheumatic disease. Best Pract Res Clin Rheumatol 32:720\u2013734. https:\/\/doi.org\/10.1016\/j.berh.2019.03.006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4917_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05700-z","author":"M Soy","year":"2021","unstructured":"Soy M, Keser G, Atagunduz P et al (2021) A practical approach for vaccinations including COVID-19 in autoimmune\/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05700-z (ahead of print)","journal-title":"Clin Rheumatol"},{"key":"4917_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-021-04792-9","volume":"41","author":"T Velikova","year":"2021","unstructured":"Velikova T, Georgiev T (2021) SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 41:509\u2013518. https:\/\/doi.org\/10.1007\/s00296-021-04792-9","journal-title":"Rheumatol Int"},{"key":"4917_CR21","doi-asserted-by":"publisher","first-page":"e001553","DOI":"10.1136\/rmdopen-2020-001553","volume":"7","author":"H Schulze-Koops","year":"2021","unstructured":"Schulze-Koops H, Specker C, Skapenko A (2021) Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. RMD Open 7:e001553. https:\/\/doi.org\/10.1136\/rmdopen-2020-001553","journal-title":"RMD Open"},{"key":"4917_CR22","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3346\/jkms.2021.36.e95","volume":"36","author":"JK Park","year":"2021","unstructured":"Park JK, Lee EB, Shin K et al (2021) COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: clinical guidance of the Korean college of rheumatology. J Korean Med Sci 36:e95. https:\/\/doi.org\/10.3346\/jkms.2021.36.e95","journal-title":"J Korean Med Sci"},{"key":"4917_CR23","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.3346\/jkms.2021.36.e59","volume":"36","author":"J Jung","year":"2021","unstructured":"Jung J (2021) Preparing for the coronavirus disease (COVID-19) vaccination: evidence, plans, and implications. J Korean Med Sci 36:e59. https:\/\/doi.org\/10.3346\/jkms.2021.36.e59","journal-title":"J Korean Med Sci"},{"issue":"1","key":"4917_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.47316\/cajmhe.2021.2.1.05","volume":"2","author":"T Velikova","year":"2021","unstructured":"Velikova T (2021) Infection-acquired versus vaccine-induced immunity against COVID-19. Cent Asian J Med Hypotheses Ethics 2(1):29\u201335. https:\/\/doi.org\/10.47316\/cajmhe.2021.2.1.05","journal-title":"Cent Asian J Med Hypotheses Ethics"},{"key":"4917_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00296-021-04817-3","volume":"41","author":"GE Fragoulis","year":"2021","unstructured":"Fragoulis GE, Grigoropoulos I, Mavrea E et al (2021) Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. Rheumatol Int 41:895\u2013902. https:\/\/doi.org\/10.1007\/s00296-021-04817-3","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04917-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:47:25Z","timestamp":1744152445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04917-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4917"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04917-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"15 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I declare that no part of this work has been published or submitted for publication. It is entirely original work and all authors fulfill ICMJE criteria for authorship.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sakir Ahmed has received honorarium as a speaker from Pfizer (not related to the current work) and has no other potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}